Merck & Co. Files 2024 Annual Report

Ticker: MRK · Form: 10-K · Filed: Feb 25, 2025 · CIK: 310158

Sentiment: neutral

Topics: annual-report, pharmaceuticals, financials

TL;DR

Merck filed its 2024 10-K, check financials and strategy.

AI Summary

Merck & Co., Inc. filed its 10-K for the fiscal year ended December 31, 2024, reporting on its operations in the pharmaceutical preparations industry. The company, headquartered in Kenilworth, NJ, is a significant player in the life sciences sector. This filing provides a comprehensive overview of its financial performance and business activities for the past fiscal year.

Why It Matters

This 10-K filing provides investors and the public with a detailed look at Merck's financial health, strategic direction, and potential risks for the fiscal year 2024.

Risk Assessment

Risk Level: medium — As a large pharmaceutical company, Merck faces inherent risks related to drug development, regulatory approvals, market competition, and patent expirations.

Key Players & Entities

FAQ

What was Merck & Co., Inc.'s fiscal year end?

Merck & Co., Inc.'s fiscal year end was December 31, 2024.

When was this 10-K filing submitted to the SEC?

This 10-K filing was submitted on February 25, 2025.

What is Merck & Co., Inc.'s Standard Industrial Classification code?

Merck & Co., Inc.'s Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.

Where is Merck & Co., Inc. headquartered?

Merck & Co., Inc. is headquartered in Kenilworth, NJ.

What is the SEC file number for Merck & Co., Inc.'s 10-K filing?

The SEC file number for Merck & Co., Inc.'s 10-K filing is 001-06571.

Filing Details

This Form 10-K (Form 10-K) was filed with the SEC on February 25, 2025 regarding Merck & Co., Inc. (MRK).

View full filing on EDGAR

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing